Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease

A technology of ethyl and compound, applied in the field of a new family of compounds, which can solve the problems of increased neurotoxicity of βA fibrils, changes in enzyme biochemical and pharmacological properties, etc.
CN1703220AInactive Publication Date: 2005-11-30NEUROPHARMA SA (ES)
1 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NEUROPHARMA SA (ES)
Publication Date
2005-11-30
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A family of compounds of formula (I) wherein: X is one of the following radicals: which behaves as dual site acetylcholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and / or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a new family of compounds that act as two-site acetylcholinesterase inhibitors, and to the synthesis and biological evaluation of said family of compounds. These compounds are particularly useful in the treatment of cognitive disorders such as senile dementia, cerebrovascular dementia, mild cognitive impairment, attention deficit disorder, and / or neurodegenerative dementia with abnormal protein aggregation, such as especially Alzheimer's disease disease, Parkinson's disease, ALS, or prion diseases such as Creutzfeldt-Jakob disease or Ger-Sch-Sarr disease.

[0002] Accordingly, the present invention also relates to pharmaceutical compositions containing said compounds. Background technique

[0003] Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is one of the most common causes of mental decline in the elderly, accounting for approximately 50-60% of all dementia cases in persons over the age of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More